Eleonora Rofi

2.2k total citations
39 papers, 1.4k citations indexed

About

Eleonora Rofi is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Eleonora Rofi has authored 39 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Oncology, 20 papers in Pulmonary and Respiratory Medicine and 17 papers in Cancer Research. Recurrent topics in Eleonora Rofi's work include Cancer Genomics and Diagnostics (15 papers), Lung Cancer Treatments and Mutations (12 papers) and Pancreatic and Hepatic Oncology Research (10 papers). Eleonora Rofi is often cited by papers focused on Cancer Genomics and Diagnostics (15 papers), Lung Cancer Treatments and Mutations (12 papers) and Pancreatic and Hepatic Oncology Research (10 papers). Eleonora Rofi collaborates with scholars based in Italy, Netherlands and China. Eleonora Rofi's co-authors include Romano Danesi, Marzia Del Re, Stefania Crucitta, Alfredo Falcone, Giuliana Restante, Stefano Fogli, Iacopo Petrini, E. Arrigoni, Mario Miccoli and Chiara Posarelli and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Scientific Reports.

In The Last Decade

Eleonora Rofi

37 papers receiving 1.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Eleonora Rofi Italy	20	631	621	583	563	148	39	1.4k
Leonel F. Hernandez‐Aya United States	17	306 0.5×	319 0.5×	325 0.6×	629 1.1×	60 0.4×	60	1.1k
Miriam Redrado Spain	20	177 0.3×	544 0.9×	270 0.5×	518 0.9×	54 0.4×	39	1.1k
Florian Castet Spain	8	379 0.6×	437 0.7×	334 0.6×	524 0.9×	55 0.4×	20	1.4k
Julia V. Burnier Canada	21	123 0.2×	592 1.0×	318 0.5×	408 0.7×	82 0.6×	73	1.2k
Ramona F. Swaby United States	22	289 0.5×	621 1.0×	278 0.5×	1.1k 1.9×	122 0.8×	83	1.8k
Thomas B. Karasic United States	16	279 0.4×	486 0.8×	282 0.5×	711 1.3×	101 0.7×	65	1.3k
Eva Muñoz‐Couselo Spain	20	418 0.7×	598 1.0×	446 0.8×	1.6k 2.9×	79 0.5×	89	2.1k
Christopher Ruel United States	18	309 0.5×	468 0.8×	131 0.2×	536 1.0×	63 0.4×	47	1.0k
Marjo Hahka‐Kemppinen Finland	18	122 0.2×	545 0.9×	198 0.3×	651 1.2×	69 0.5×	33	1.1k
Erika von Euw United States	18	269 0.4×	893 1.4×	209 0.4×	757 1.3×	66 0.4×	30	1.6k

Countries citing papers authored by Eleonora Rofi

Since Specialization

Citations

This map shows the geographic impact of Eleonora Rofi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eleonora Rofi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eleonora Rofi more than expected).

Fields of papers citing papers by Eleonora Rofi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eleonora Rofi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eleonora Rofi. The network helps show where Eleonora Rofi may publish in the future.

Co-authorship network of co-authors of Eleonora Rofi

This figure shows the co-authorship network connecting the top 25 collaborators of Eleonora Rofi. A scholar is included among the top collaborators of Eleonora Rofi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eleonora Rofi. Eleonora Rofi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Vivaldi, Caterina, Stefania Crucitta, Silvia Catanese, et al.. (2021). Comprehensive pharmacogenetic analysis of DPYD, UGT, CDA, and ABCB1 polymorphisms in pancreatic cancer patients receiving mFOLFIRINOX or gemcitabine plus nab-paclitaxel. The Pharmacogenomics Journal. 21(2). 233–242. 11 indexed citations

Re, Marzia Del, Federico Cucchiara, Eleonora Rofi, et al.. (2020). A multiparametric approach to improve the prediction of response to immunotherapy in patients with metastatic NSCLC. Cancer Immunology Immunotherapy. 70(6). 1667–1678. 28 indexed citations

Cucchiara, Federico, Marzia Del Re, Chiara Romei, et al.. (2020). Integrating Liquid Biopsy and Radiomics to Monitor Clonal Heterogeneity of EGFR-Positive Non-Small Cell Lung Cancer. Frontiers in Oncology. 10. 593831–593831. 30 indexed citations

Re, Marzia Del, Eleonora Rofi, Carla Cappelli, et al.. (2019). The increase in activating EGFR mutation in plasma is an early biomarker to monitor response to osimertinib: a case report. BMC Cancer. 19(1). 410–410. 13 indexed citations

Re, Marzia Del, Iacopo Petrini, Francesca Mazzoni, et al.. (2019). Incidence of T790M in Patients With NSCLC Progressed to Gefitinib, Erlotinib, and Afatinib: A Study on Circulating Cell-free DNA. Clinical Lung Cancer. 21(3). 232–237. 24 indexed citations

Rofi, Eleonora, Marzia Del Re, E. Arrigoni, et al.. (2019). Clinical pharmacology of monoclonal antibodies targeting anti-PD-1 axis in urothelial cancers. Critical Reviews in Oncology/Hematology. 144. 102812–102812. 10 indexed citations

Bordi, Paola, Marzia Del Re, Roberta Minari, et al.. (2019). From the beginning to resistance: Study of plasma monitoring and resistance mechanisms in a cohort of patients treated with osimertinib for advanced T790M-positive NSCLC. Lung Cancer. 131. 78–85. 42 indexed citations

Re, Marzia Del, Ilaria Bertolini, Stefania Crucitta, et al.. (2019). Overexpression of TK1 and CDK9 in plasma-derived exosomes is associated with clinical resistance to CDK4/6 inhibitors in metastatic breast cancer patients. Breast Cancer Research and Treatment. 178(1). 57–62. 79 indexed citations

Fogli, Stefano, Marzia Del Re, Eleonora Rofi, et al.. (2018). Clinical pharmacology of intravitreal anti-VEGF drugs. Eye. 32(6). 1010–1020. 164 indexed citations

10.

Re, Marzia Del, Paola Bordi, Eleonora Rofi, et al.. (2018). The amount of activating EGFR mutations in circulating cell-free DNA is a marker to monitor osimertinib response. British Journal of Cancer. 119(10). 1252–1258. 38 indexed citations

11.

Re, Marzia Del, Stefania Crucitta, Giuliana Restante, et al.. (2018). Pharmacogenetics of androgen signaling in prostate cancer: Focus on castration resistance and predictive biomarkers of response to treatment. Critical Reviews in Oncology/Hematology. 125. 51–59. 7 indexed citations

12.

Re, Marzia Del, Riccardo Marconcini, G. Pasquini, et al.. (2018). PD-L1 mRNA expression in plasma-derived exosomes is associated with response to anti-PD-1 antibodies in melanoma and NSCLC. British Journal of Cancer. 118(6). 820–824. 205 indexed citations

13.

Re, Marzia Del, E. Arrigoni, Giuliana Restante, et al.. (2018). Concise Review: Resistance to Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer: The Role of Cancer Stem Cells. Stem Cells. 36(5). 633–640. 33 indexed citations

14.

Bordi, Paola, Marcello Tiseo, Eleonora Rofi, et al.. (2017). Detection of ALK and KRAS Mutations in Circulating Tumor DNA of Patients With Advanced ALK-Positive NSCLC With Disease Progression During Crizotinib Treatment. Clinical Lung Cancer. 18(6). 692–697. 45 indexed citations

15.

Vivaldi, Caterina, E. Arrigoni, Riccardo Morganti, et al.. (2017). Analysis of DPYD and UGT1A1 genotype in patients with advanced pancreatic cancer treated with modified FOLFIRINOX. Annals of Oncology. 28. vi48–vi48. 1 indexed citations

16.

Re, Marzia Del, Paola Bordi, Iacopo Petrini, et al.. (2017). Patients with NSCLC may display a low ratio of p.T790M vs. activating EGFR mutations in plasma at disease progression: implications for personalised treatment. Oncotarget. 8(49). 86056–86065. 11 indexed citations

17.

Re, Marzia Del, Caterina Vivaldi, Eleonora Rofi, et al.. (2017). Early changes in plasma DNA levels of mutant KRAS as a sensitive marker of response to chemotherapy in pancreatic cancer. Scientific Reports. 7(1). 7931–7931. 70 indexed citations

18.

Re, Marzia Del, et al.. (2017). Should CYP2D6 be Genotyped When Treating with Tamoxifen?. Pharmacogenomics. 18(8). 755–756. 2 indexed citations

19.

Re, Marzia Del, Elisa Biasco, Stefania Crucitta, et al.. (2016). AR-V7 detection in plasma-derived exosomal RNA strongly predicts resistance to hormonal therapy in metastatic prostate cancer. Annals of Oncology. 27. vi248–vi248. 1 indexed citations

20.

Re, Marzia Del, Elisa Biasco, Stefania Crucitta, et al.. (2016). The Detection of Androgen Receptor Splice Variant 7 in Plasma-derived Exosomal RNA Strongly Predicts Resistance to Hormonal Therapy in Metastatic Prostate Cancer Patients. European Urology. 71(4). 680–687. 224 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact